Stocks and Investing Stocks and Investing
Mon, August 2, 2021
Sun, August 1, 2021
Fri, July 30, 2021

David Lebovitz Maintained (BPMC) at Hold with Decreased Target to $96 on, Jul 30th, 2021


Published on 2024-10-27 17:26:22 - WOPRAI, David Lebovitz
  Print publication without navigation


David Lebovitz of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Decreased Target from $101 to $96 on, Jul 30th, 2021.

David has made no other calls on BPMC in the last 4 months.



There are 5 other peers that have a rating on BPMC. Out of the 5 peers that are also analyzing BPMC, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Brad Canino of "Credit Suisse" Initiated at Hold and Held Target at $100 on, Wednesday, March 31st, 2021


These are the ratings of the 4 analyists that currently disagree with David


  • Andrew Berens of "SVB Leerink" Maintained at Buy with Increased Target to $137 on, Thursday, June 17th, 2021
  • Joel Beatty of "Baird" Maintained at Buy with Increased Target to $123 on, Thursday, June 17th, 2021
  • Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $130 on, Thursday, June 17th, 2021
  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Decreased Target to $110 on, Thursday, April 29th, 2021
Contributing Sources